For the quarter ending 2025-09-30, NAUT had -$10,582K decrease in cash & cash equivalents over the period. -$11,452K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -13,574 | -31,646 |
| Stock-based compensation expense | 1,496 | 3,877 |
| Amortization of operating lease right-of-use assets | 1,193 | 2,336 |
| Depreciation | 426 | 922 |
| Amortization (accretion) of premium (discount) on securities, net | 306 | 980 |
| Prepaid expenses and other assets | 11 | -160 |
| Accounts payable | -20 | -51 |
| Accrued expenses and other liabilities | 942 | 390 |
| Operating lease liabilities | -1,180 | -2,295 |
| Net cash used in operating activities | -11,034 | -27,287 |
| Proceeds from maturities of securities | 28,363 | 45,878 |
| Purchases of securities | 27,493 | 11,278 |
| Purchases of property and equipment | 418 | 615 |
| Net cash provided by investing activities | 452 | 33,985 |
| Proceeds from exercise of stock options | 0 | 26 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 87 |
| Net cash provided by financing activities | 0 | 113 |
| Net decrease in cash, cash equivalents and restricted cash | -10,582 | 6,811 |
| Cash and cash equivalents at beginning of period | 28,648 | - |
| Cash and cash equivalents at end of period | 24,877 | - |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)